Publication|Articles|September 2, 2026

MHE Publication

  • MHE September 2026
  • Volume 36
  • Issue 9

Product Profile: Simtriyo (centanafadine)

The FDA approved July 2026 Simtriyo, a new type of medication for patients with attention-deficit hyperactivity disorder (ADHD).

Learn about a new product for ADHD.